An Orally Available BACE1 Inhibitor That Affords Robust CNS A beta Reduction without Cardiovascular Liabilities.
Cheng, Y., Brown, J., Judd, T.C., Lopez, P., Qian, W., Powers, T.S., Chen, J.J., Bartberger, M.D., Chen, K., Dunn, R.T., Epstein, O., Fremeau, R.T., Harried, S., Hickman, D., Hitchcock, S.A., Luo, Y., Minatti, A.E., Patel, V.F., Vargas, H.M., Wahl, R.C., Weiss, M.M., Wen, P.H., White, R.D., Whittington, D.A., Zheng, X.M., Wood, S.(2015) ACS Med Chem Lett 6: 210-215
- PubMed: 25699151 
- DOI: 10.1021/ml500458t
- Primary Citation of Related Structures:  
4WTU - PubMed Abstract: 
BACE1 inhibition to prevent Aβ peptide formation is considered to be a potential route to a disease-modifying treatment for Alzheimer's disease. Previous efforts in our laboratory using a combined structure- and property-based approach have resulted in the identification of aminooxazoline xanthenes as potent BACE1 inhibitors ...